Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 50Lymphoma, Non-Hodgkin 36Lymphoma, Large B-Cell, Diffuse 29Lymphoma 29Lymphoma, Mantle-Cell 26Lymphoma, B-Cell, Marginal Zone 22Lymphoma, B-Cell 18Recurrence 13Neoplasms 11Leukemia 7Leukemia, B-Cell 6Burkitt Lymphoma 5Leukemia, Hairy Cell 4Waldenstrom Macroglobulinemia 3Neoplasm, Residual 3Melanoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Disease 2Dendritic Cell Sarcoma, Interdigitating 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Tumor Lysis Syndrome 1Solid Cancers 1

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11130-nm albumin-bound paclitaxel 11Sunitinib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × obinutuzumab × Clear all
NCT04787042 2024-11-15

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Simcha IL-18, Inc.

Phase 1/2 Recruiting
316 enrolled
BreastDermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡